Tenaya Therapeutics预计2026年上半年公布Tn-401治疗PKP2相关ARVC的Ridge-1研究一年期队列1数据及早期队列2数据

美股速递
Jan 09

Tenaya Therapeutics Inc宣布,针对PKP2相关致心律失常性右室心肌病(ARVC)的基因疗法Tn-401,其Ridge-1临床研究预计将于2026年上半年公布重要进展。届时将披露队列1患者接受治疗满一年的随访数据,同时公布队列2研究的早期结果。

该时间规划凸显了公司对推进罕见心脏病创新疗法的承诺。Ridge-1研究数据的陆续出炉,将为评估Tn-401疗法的安全性与有效性提供关键依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10